News

Alto Neuroscience's ALTO-101 gains FDA Fast Track designation, promising a novel treatment for cognitive impairment in schizophrenia.

Review the September Special Report with articles on geriatric psychiatry, from a variety of experts.

H. Steven Moffic, MD, explores the ongoing challenges for women in the military and society, highlighting the need for recognition of their unique contributions.

A new study reveals the ReCODE program significantly reduces depression in patients with cognitive impairment, enhancing both mood and cognitive health.

Reproductive psychiatrist Sarah Oreck, MD, MS challenges the FDA's claims linking acetaminophen use in pregnancy to autism and ADHD, advocating for informed maternal care.

Explore powerful memoirs that delve into addiction, recovery, and the emotional struggles faced by individuals and families in the journey to healing.

The Ububele Educational and Psychotherapy Trust enhances mental health access in South Africa, focusing on early childhood support and community-based interventions to break cycles of emotional poverty.

Bristol Myers Squibb's BMS-986446 receives FDA Fast Track Designation, aiming to transform early Alzheimer disease treatment by targeting tau pathology.

Socrates’ suicide as an affirmative choice.

Late-life depression poses unique challenges, impacting cognitive function and requiring tailored treatment strategies for older adults.

Explore how lifestyle choices like diet, exercise, and sleep enhance mental health outcomes in psychiatry. Share your insights and experiences today with our October theme!

Recent research links nighttime screen use and easy medication access to increased suicide attempts among adolescents, highlighting urgent mental health concerns.

Lipocine Inc. advances LPCN 1154, an oral treatment for postpartum depression, aiming for rapid relief and improved patient access by 2026.

Explore the dramatic evolution of AI, from early concepts to modern chatbots, and the uncertain future they create for humanity.

What disease states are most prominently featured in recent research? Learn more in this exclusive article.

Exploring the intersection of free speech and psychiatry, this article examines societal risks and the ethical responsibilities of mental health professionals.

New phase 3 data highlights seltorexant's potential as a safer adjunctive treatment for major depressive disorder with insomnia, despite not meeting primary end points. Andrew J. Cutler, MD, shares his thoughts.

Psychiatry explores extraordinary experiences like near-death experiences and out-of-body experiences, distinguishing them from mental illness to enhance patient care and understanding.

INmune Bio reveals phase 2 trial results for XPro1595, a novel treatment targeting neuroinflammation in early Alzheimer disease.

In this CME article, explore the complexities of movement disorders in psychiatric practice, including their causes, symptoms, and treatment strategies for better patient care.

Anebulo Pharmaceuticals initiates a phase 1 trial for selonabant, targeting acute cannabis toxicity in children with promising IV treatment potential.

A new study reveals tasimelteon (Hetlioz) significantly improves sleep onset in chronic insomnia patients.

Explore the challenges and strategies of deprescribing in geriatric psychiatry to enhance patient safety and reduce polypharmacy risks.

Explore the evolving understanding of autism, Tylenol use in pregnancy, and the importance of neurodiversity in today's society.

A new study reveals the overwhelming financial and emotional burdens faced by caregivers of individuals with schizophrenia, highlighting urgent support needs.

Geriatric psychiatry faces a growing demand for care. Collaborative models enhance access and improve outcomes for older adults with mental health needs.

Synendos Therapeutics reveals promising phase 1 results for SYT-510, a novel ECS modulator targeting anxiety and CNS disorders with potential for improved patient outcomes.

"Two ways of talking and living in the world.”

A phase 2 study reveals osavampator significantly reduces depression severity in adults with major depressive disorder, showing promise for treatment-resistant cases.

Younger veterans face significantly higher PTSD rates due to social challenges.